List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Familial Adenomatous Polyposis - Overview
Familial Adenomatous Polyposis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Familial Adenomatous Polyposis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Familial Adenomatous Polyposis - Companies Involved in Therapeutics Development
ADT Pharmaceuticals Inc
Cancer Prevention Pharmaceuticals Inc
Cellix Bio Pvt Ltd
DNAlite Therapeutics Inc
Emtora Biosciences
FunPep Co Ltd
GLW Pharma
Johnson & Johnson
Stemsynergy Therapeutics Inc
TherapyX Inc
Thetis Pharmaceuticals LLC
Zikani Therapeutics Inc
Familial Adenomatous Polyposis - Drug Profiles
(eflornithine hydrochloride + sulindac) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLXONC-57 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FAPXIL SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Familial Adenomatous Polyposis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
guselkumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Familial Adenomatous Polyposis - Dormant Projects
Familial Adenomatous Polyposis - Discontinued Products
Familial Adenomatous Polyposis - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Familial Adenomatous Polyposis, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Familial Adenomatous Polyposis - Pipeline by ADT Pharmaceuticals Inc, H2 2020
Familial Adenomatous Polyposis - Pipeline by Cancer Prevention Pharmaceuticals Inc, H2 2020
Familial Adenomatous Polyposis - Pipeline by Cellix Bio Pvt Ltd, H2 2020
Familial Adenomatous Polyposis - Pipeline by DNAlite Therapeutics Inc, H2 2020
Familial Adenomatous Polyposis - Pipeline by Emtora Biosciences, H2 2020
Familial Adenomatous Polyposis - Dormant Projects, H2 2020
Familial Adenomatous Polyposis - Discontinued Products, H2 2020

List of Figures
Number of Products under Development for Familial Adenomatous Polyposis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020

Companies Mentioned
• ADT Pharmaceuticals Inc
• Cancer Prevention Pharmaceuticals Inc
• Cellix Bio Pvt Ltd
• DNAlite Therapeutics Inc
• Emtora Biosciences
• FunPep Co Ltd
• GLW Pharma
• Johnson & Johnson
• Stemsynergy Therapeutics Inc
• TherapyX Inc
• Thetis Pharmaceuticals LLC
• Zikani Therapeutics Inc